| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/06/2002 | WO2002068444A1 Ttk in diagnosis and as a therapeutic target in cancer |
| 09/06/2002 | WO2002068436A1 Avilamycin derivatives |
| 09/06/2002 | WO2002068427A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
| 09/06/2002 | WO2002068425A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists |
| 09/06/2002 | WO2002068424A1 Indole derivatives having an inhibitory effect on protein kinases |
| 09/06/2002 | WO2002068423A1 Novel substituted imidazotriazinones |
| 09/06/2002 | WO2002068421A2 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 09/06/2002 | WO2002068420A1 Xanthine derivative, production and use thereof as a medicament |
| 09/06/2002 | WO2002068419A1 Pyridopyrimidine or naphthyridine derivative |
| 09/06/2002 | WO2002068417A2 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068414A2 Analogs of thalidomide as potential angiogenesis inhibitors |
| 09/06/2002 | WO2002068412A1 Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment |
| 09/06/2002 | WO2002068410A1 Substituted pyrimidinone derivatives as ligands of integrin receptors |
| 09/06/2002 | WO2002068409A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| 09/06/2002 | WO2002068406A2 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 09/06/2002 | WO2002068404A1 Method for producing optically active dihydropyrones |
| 09/06/2002 | WO2002068399A1 Aryl carbamate derivatives, preparation and use thereof |
| 09/06/2002 | WO2002068398A1 New crystal forms of lamotrigine and processes for their preparations |
| 09/06/2002 | WO2002068397A1 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors |
| 09/06/2002 | WO2002068396A1 Combi-molecules having signal transduction inhibitory properties and dna damaging properties |
| 09/06/2002 | WO2002068395A1 Hiv inhibiting n-aminoimidazole derivatives |
| 09/06/2002 | WO2002068393A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 09/06/2002 | WO2002068390A1 Diamides which inhibit tryptase and factor xa activity |
| 09/06/2002 | WO2002068389A2 Indole derivatives with inhibitor effects on phenol oxidase |
| 09/06/2002 | WO2002068388A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002068387A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002068383A2 Thiol-modified hyaluronan |
| 09/06/2002 | WO2002068381A2 Aryl-n-cyanoguanidines and methods related thereto |
| 09/06/2002 | WO2002068377A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells |
| 09/06/2002 | WO2002068058A2 Dapd combination therapy with imdph inhibitors such as ribavirin or mycophenolic acid |
| 09/06/2002 | WO2002068057A1 Barbiturates as integrin antagonists and their use for treating inflammatory diseases |
| 09/06/2002 | WO2002068056A2 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside |
| 09/06/2002 | WO2002068015A2 Modular infusion device and method |
| 09/06/2002 | WO2002067998A2 Devices and methods for the treatment of cancer |
| 09/06/2002 | WO2002067994A2 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 09/06/2002 | WO2002067990A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | WO2002067988A2 Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor |
| 09/06/2002 | WO2002067987A2 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent |
| 09/06/2002 | WO2002067983A1 Novel vaccine |
| 09/06/2002 | WO2002067975A1 Negative regulation of epidermal growth factor receptor activity by mig-6 |
| 09/06/2002 | WO2002067974A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis |
| 09/06/2002 | WO2002067968A2 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 09/06/2002 | WO2002067966A1 Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
| 09/06/2002 | WO2002067965A1 Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer |
| 09/06/2002 | WO2002067964A1 Compositions and methods for cancer prevention and treatment derived from $i(inula britannica) |
| 09/06/2002 | WO2002067962A1 The method for preparating an anemone raddeana extract and the pharmaceutical composition containing the same as well as use thereof |
| 09/06/2002 | WO2002067961A2 Therapeutic uses of herbal compositions |
| 09/06/2002 | WO2002067960A1 Herbal compositions useful as chemopreventive and therapeutic agents |
| 09/06/2002 | WO2002067959A1 Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and prepairing process thereof |
| 09/06/2002 | WO2002067958A1 Method for determining efficacy of reverse cholesterol transport enhancing agents |
| 09/06/2002 | WO2002067955A2 A process for the manufacture of a herbal composition comprising a matrine |
| 09/06/2002 | WO2002067953A2 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |
| 09/06/2002 | WO2002067952A1 Prophylactic teat treatment |
| 09/06/2002 | WO2002067951A2 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 09/06/2002 | WO2002067950A1 Vascular regeneration promoters |
| 09/06/2002 | WO2002067949A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia |
| 09/06/2002 | WO2002067948A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder |
| 09/06/2002 | WO2002067947A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for adjuvant treatment of perianal disease |
| 09/06/2002 | WO2002067946A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| 09/06/2002 | WO2002067945A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion |
| 09/06/2002 | WO2002067944A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating motion sickness |
| 09/06/2002 | WO2002067943A1 Oral pharmaceutical composition of cefpodoxime proxetil |
| 09/06/2002 | WO2002067942A2 Methods of treating irritable bowel syndrome and functional dyspepsia |
| 09/06/2002 | WO2002067941A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 09/06/2002 | WO2002067940A1 Application of phenazinone derivatives in preparing antitumor and antimetastases drugs |
| 09/06/2002 | WO2002067939A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | WO2002067938A2 Treating or reducing the risk of cardiovascular disease |
| 09/06/2002 | WO2002067937A1 Indoline and tetrahydro-quinolines as prodrugs for tumour treatment |
| 09/06/2002 | WO2002067936A1 Methods for treatment of inflammatory bowel disease |
| 09/06/2002 | WO2002067935A1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 09/06/2002 | WO2002067934A1 New use of phencynonate hydrochloride |
| 09/06/2002 | WO2002067933A1 New use of phencynonate hydrochloride |
| 09/06/2002 | WO2002067932A1 Antihelminthic drugs as a treatment for hyperproliferative diseases |
| 09/06/2002 | WO2002067931A1 Treatment of tics, tremors and related disorders |
| 09/06/2002 | WO2002067930A1 Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
| 09/06/2002 | WO2002067928A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 09/06/2002 | WO2002067927A1 Carbamate compounds for use in preventing or treating psychotic disorders |
| 09/06/2002 | WO2002067926A1 Carbamate compounds for use in preventing or treating movement disorders |
| 09/06/2002 | WO2002067925A1 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 09/06/2002 | WO2002067924A1 Carbamate compounds for use in preventing or treating bipolar disorder |
| 09/06/2002 | WO2002067923A1 Carbamate compounds for use in preventing or treating anxiety disorders |
| 09/06/2002 | WO2002067922A1 Carbamate compounds for use in the treatment of pain |
| 09/06/2002 | WO2002067921A1 Carbamate compounds for use in preventing or treating bipolar disorder |
| 09/06/2002 | WO2002067920A1 Remedies for chronic hepatitis c |
| 09/06/2002 | WO2002067919A1 Il-8 receptor antagonists |
| 09/06/2002 | WO2002067918A1 Novel diallylmethylamine derivative |
| 09/06/2002 | WO2002067916A2 Pharmaceutical salts |
| 09/06/2002 | WO2002067915A1 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 09/06/2002 | WO2002067913A1 (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| 09/06/2002 | WO2002067912A2 Method for treating ppar gamma mediated diseases or conditions |
| 09/06/2002 | WO2002067911A1 Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels |
| 09/06/2002 | WO2002067910A2 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
| 09/06/2002 | WO2002067909A1 New method of bronchodilatory therapy |
| 09/06/2002 | WO2002067908A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | WO2002067904A1 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
| 09/06/2002 | WO2002067903A2 Compositions and methods of manufacture for oral dissolvable dosage forms |
| 09/06/2002 | WO2002067902A2 Modulation of release from dry powder formulations |
| 09/06/2002 | WO2002067901A1 Fibrate-statin combinations with reduced fed-fasted effects |
| 09/06/2002 | WO2002067900A1 Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same |